Target Delivery of a Novel Antitumor Organoplatinum(IV)-Substituted Polyoxometalate Complex for Safer and More Effective Colorectal Cancer Therapy In Vivo

Adv Mater. 2016 Sep;28(34):7397-404. doi: 10.1002/adma.201601778. Epub 2016 Jun 16.

Abstract

An inactive organoplatinum(IV)-substituted polyoxometalate is developed as an efficient and nontoxic prodrug with significant potential for treating human colorectal cancers. Further encapsulation of Pt(IV) -PW11 with DSPE-PEG2000 nanoparticles (NPs) enables targeted delivery and controlled release of inactive prodrug. Such Pt(IV) -PW11 -DSPE-PEG2000 NPs are highly efficient in inhibiting cellular growth of HT29 cells and treating human colorectal cancer in mice, superior to classic cisplatin.

Keywords: antitumor activity; micelles; polyoxometalates; target delivery.

MeSH terms

  • Animals
  • Antineoplastic Agents
  • Cell Line, Tumor
  • Cisplatin
  • Colorectal Neoplasms*
  • Drug Delivery Systems
  • Humans
  • Mice
  • Nanoparticles
  • Prodrugs
  • Tungsten Compounds

Substances

  • Antineoplastic Agents
  • Prodrugs
  • Tungsten Compounds
  • polyoxometalate I
  • Cisplatin